SLC25A13: A Drug Target / Disease Biomarker (G10165)

Target Name: SLC25A13

NCBI ID: G10165

SLC25A13

SLC25A13: A Drug Target / Disease Biomarker

SLC25A13 is a protein that is expressed in various tissues throughout the body, including the brain, heart, liver, and kidney. It is a member of the SLC (sodium-glucose cotransporter) family, which is responsible for transporting glucose and sodium ions across cell membranes. SLC25A13 is expressed in high levels in the brain, where it is involved in the regulation of glucose metabolism and neurotransmitter release.

SLC25A13 has also been identified as a potential drug target in the treatment of various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression. Studies have shown that individuals with certain genetic variations in the SLC25A13 gene are at an increased risk of developing these disorders, and that modulating SLC25A13 activity may be a promising new approach to treatment.

In addition to its potential therapeutic applications, SLC25A13 has also been the subject of significant research in the fields of neurobiology and pharmacology. Researchers have used a variety of techniques, including RNA sequencing and live cell imaging, to study its function and interactions with other proteins. This knowledge has provided insights into the underlying mechanisms that regulate SLC25A13 activity and has identified potential targets for intervention.

One of the key challenges in studying SLC25A13 is its high level of expression in various tissues, which can make it difficult to study its effects in isolation. Researchers have used techniques such as RNA interference and CRISPR/Cas9 genome editing to reduce the expression of SLC25A13 and study its effects on specific cellular processes. This has allowed them to determine the precise role that SLC25A13 plays in the regulation of glucose metabolism and neural function.

In addition to its potential therapeutic applications, SLC25A13 has also been identified as a potential biomarker for the assessment of disease status in individuals with neurological disorders. Studies have shown that the levels of SLC25A13 are often decreased in individuals with Alzheimer's disease and other neurological disorders, and that increased levels of SLC25A13 have been associated with improved cognitive function and reduced disease severity in these individuals. This suggests that SLC25A13 may be a useful diagnostic tool for the assessment of disease status in individuals with neurological disorders.

Overall, SLC25A13 is a protein that has significant potential as a drug target and biomarker for the treatment of neurological and psychiatric disorders. Further research is needed to fully understand its function and interactions with other proteins, and to develop effective treatments based on these insights.

Protein Name: Solute Carrier Family 25 Member 13

Functions: Mitochondrial electrogenic aspartate/glutamate antiporter that favors efflux of aspartate and entry of glutamate and proton within the mitochondria as part of the malate-aspartate shuttle (PubMed:11566871). Also mediates the uptake of L-cysteinesulfinate by mitochondria in exchange of L-glutamate and proton. Can also exchange L-cysteinesulfinate with aspartate in their anionic form without any proton translocation (PubMed:11566871)

The "SLC25A13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC25A13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets